We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
+42.67%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$1.86B
AUM Growth
+$458M
Cap. Flow
+$74.4M
Cap. Flow %
4%
Top 10 Hldgs %
60.44%
Holding
79
New
30
Increased
3
Reduced
8
Closed
14

Top Buys

Rank Stock Value
1
SPRY icon
ARS Pharmaceuticals
SPRY
+$84.6M
2
STTK icon
Shattuck Labs
STTK
+$79M
3
SLDB icon
Solid Biosciences
SLDB
+$33.6M
4
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$18.9M
5
ORIC icon
Oric Pharmaceuticals
ORIC
+$12.9M

Top Sells

Rank Stock Value
1
KURA icon
Kura Oncology
KURA
+$99.6M
2
STRO icon
Sutro Biopharma
STRO
+$50M
3
SURF
Surface Oncology, Inc. Common Stock
SURF
+$28.5M
4
ASMB icon
Assembly Biosciences
ASMB
+$24.9M
5
CBIO
Crescent Biopharma
CBIO
+$11.4M

Sector Composition

Rank Sector Weight
1 Healthcare 93.73%
2 Miscellaneous 5.76%
3 Financials 0.51%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XNCR icon
1
Xencor
XNCR
$1.94B
$198M 10.67%
4,547,072
– –
RLAY icon
2
Relay Therapeutics
RLAY
$4.11B
$133M 7.15%
3,200,649
– –
STTK icon
3
Shattuck Labs
STTK
$707M
$129M 6.92%
+2,456,854
New +$79M
SPRY icon
4
ARS Pharmaceuticals
SPRY
$586M
$117M 6.31%
+2,533,635
New +$84.6M
PRTA icon
5
Prothena Corp
PRTA
$479M
$113M 6.09%
9,426,640
– –
ORIC icon
6
Oric Pharmaceuticals
ORIC
$1.37B
$105M 5.63%
3,092,218
+450,000
+17% +$12.9M
MRTX
7
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$102M 5.48%
464,298
– –
MORF
8
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$95.3M 5.12%
2,839,884
– –
ANAB icon
9
AnaptysBio
ANAB
$1.67B
$69.3M 3.73%
3,223,324
– –
BIIB icon
10
CALL
Biogen
BIIB
$32.3B
$62.2M 3.34%
+254,100
New +$65.6M
SLDB icon
11
Solid Biosciences
SLDB
$1.05B
$60.5M 3.25%
+531,847
New +$33.6M
KURA icon
12
Kura Oncology
KURA
$1.13B
$57.9M 3.11%
1,773,037
-2,835,492
-62% -$99.6M
RCUS icon
13
Arcus Biosciences
RCUS
$3.72B
$57M 3.06%
2,195,892
+385,892
+21% +$9.34M
RNAM
14
DELISTED
Avidity Biosciences
RNAM
$53.7M 2.89%
2,103,950
– –
NRIX icon
15
Nurix Therapeutics
NRIX
$2.72B
$50.8M 2.73%
1,544,019
+351,863
+30% +$11.7M
NGNE icon
16
Neurogene
NGNE
$732M
$44M 2.37%
156,135
-37,012
-19% -$9.04M
BCEL
17
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$39.2M 2.11%
2,426,685
– –
AKUS
18
DELISTED
Akouos Inc
AKUS
$39.2M 2.11%
1,975,984
– –
AMTI
19
DELISTED
Applied Molecular Transport Inc. Common Stock
AMTI
$35.4M 1.9%
1,150,000
– –
GERN icon
20
Geron
GERN
$970M
$30.1M 1.62%
18,939,925
-290,844
-2% -$530K
KDNY
21
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$19.8M 1.07%
+1,250,001
New +$18.9M
KLRS
22
Kalaris Therapeutics
KLRS
$95.9M
$17.2M 0.92%
19,435
– –
GRTS
23
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$13.5M 0.72%
+3,421,287
New +$10.3M
ACIU icon
24
AC Immune
ACIU
$263M
$12.5M 0.67%
+2,410,240
New +$12.3M
KRON
25
DELISTED
Kronos Bio
KRON
$11.6M 0.62%
+387,357
New +$12.2M
1
2 3 4

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q4 2020 Portfolio in Review

As of Q4 2020, EcoR1 Capital held 79 positions worth $1.86B, up 33% from $1.4B the previous quarter. Its ten largest holdings account for 60% of the portfolio.

EcoR1 Capital deployed $74.4M of net new capital in Q4 2020, opening 30 new positions and adding to 3 existing holdings. Its largest new stake was ARS Pharmaceuticals: 2,533,635 shares worth $117M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 96% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was Kura Oncology, an estimated $99.6M trimmed.

  • EcoR1 Capital's largest Q4 2020 buy was ARS Pharmaceuticals: 2,533,635 shares worth $117M.
  • EcoR1 Capital added most to Oric Pharmaceuticals in Q4 2020, an estimated $12.9M increase.
  • EcoR1 Capital's biggest Q4 2020 reduction was Kura Oncology, cutting an estimated $99.6M.
  • EcoR1 Capital fully exited Assembly Biosciences in Q4 2020, selling an estimated $24.9M.
  • EcoR1 Capital's ten largest holdings make up 60% of its $1.86B portfolio in Q4 2020.
  • EcoR1 Capital opened 30 new positions and closed 14 in Q4 2020.
  • EcoR1 Capital's portfolio value rose 33% quarter-over-quarter to $1.86B.

Based on EcoR1 Capital's 13F filing for Q4 2020, filed 16 Feb 2021.